xMedica

NCT06535854ClinicalTrials.gov

Prevail Global Study

A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.

Interventionell1.205 Teilnehmende gesucht51 Studienzentren1 Land

Kategorien

Herz-Kreislauf100%

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2024-08-02; recorded start 2025-02-24
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Uses blinding (masking)A masking level is recorded in the record
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 10 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Vascular)
  • No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 51 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,205 participants (target), run at 51 sites.

How this score is built
  • Enrolment31/40

    1,205 participants (target)

  • Site count20/25

    51 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 72 months

  • Sponsor scale3/10

    Medtronic Vascular has led 11 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.

The Prevail Global study is a prospective, premarket, interventional, multi-center, global, dual cohort clinical study enrolling subjects undergoing percutaneous coronary intervention for in-stent restenosis (ISR Cohort) in a randomized controlled study of the Prevail Drug-Coated Balloon, and subjects undergoing percutaneous coronary intervention of the Prevail Drug-Coated Balloon for de novo lesions in small vessel disease (DNSV Cohort) in a single arm prospectively enrolled study. In the ISR Cohort this will be accomplished by randomizing subjects to either a Prevail DCB arm or an Agent DCB arm to compare results of the treatment of ISR with coronary lesions previously treated with DES or BMS in native coronary arteries. In the DNSV Cohort this will be accomplished through collection of data to compare results of the Prevail DCB to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease. Subjects will be enrolled at approximately 65 study sites; the same study sites will be used for enrollment of both cohorts. The enrollment period is anticipated to be approximately 12 months. Subjects will remain in the study with follow-up clinical assessments through 5 years, study exit, or death, whichever comes first.

Erkrankungen

  • Coronary Artery Disease

Eignung

GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * ≥ 18 years * Negative pregnancy test * Stable or unstable angina, positive functional test, or stable NSTEMI * Life expectancy \>1 year * Willing and able to cooperate with study procedures and required follow up evaluations Exclusion Criteria: * Known hypersensitivity or contraindication to antiplatelet medications or a sensitivity to contrast media which cannot be adequately pre-medicated * History of an allergic reaction or significant sensitivity to paclitaxel or any other analogue or derivative * Platelet count \< 100,000 cells/mm³ or \> 700,000 cells/mm³, or a white blood cell (WBC) count \< 3,000 cells/mm³ * Renal insufficiency (or failure) * Acute MI * Previous PCI of the target vessel within 6 months prior to the procedure * Planned PCI of any vessel within 30 days post-index procedure and/or planned PCI of the target vessel within 12 months post-procedure * History of a stroke or transient ischemic attack (TIA) * Active peptic ulcer or upper gastrointestinal (GI) bleeding * History of bleeding diathesis or coagulopathy or will refuse blood transfusions * Documented left ventricular ejection fraction (LVEF) \<30% * Planned surgery that would cause interruption in recommended DAPT duration per current guidelines * Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS or other coronary artery imaging procedures

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

StudientypInterventionell
PhaseNicht zutreffend
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungSINGLE (1)
Teilnahme1.205 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Medtronic Vascular Sponsor

Studienarme und Interventionen

  • ISR Cohort Prevail DCBEXPERIMENTAL

    To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.

  • DNSV Cohort (RVD 2.0 - 2.75mm)EXPERIMENTAL

    To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.

Interventionen

  • Medizinprodukt Agent DCB

    The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).

  • Medizinprodukt Prevail DCB

    The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.

Endpunkte

  1. Primärer Endpunkt

    ISR Cohort Primary Analysis

    The TLF rate of the Prevail DCB arm at 12 months post procedure compared to the Agent DCB arm for non-inferiority

    Zeitrahmen 1 year post-procedure

  2. Primärer Endpunkt

    DNSV Cohort Primary Analysis

    The TLF rate of the Prevail DCB arm at 12 months post procedure compared to a DES historical control

    Zeitrahmen 1 year post-procedure

  3. Sekundärer Endpunkt

    Acute success

    Acute success (device, lesion, and procedure) through hospital discharge only

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  4. Sekundärer Endpunkt

    All deaths

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  5. Sekundärer Endpunkt

    Cardiac death

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  6. Sekundärer Endpunkt

    All myocardial infarction (MI), including target vessel myocardial infarction (TVMI)

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  7. Sekundärer Endpunkt

    Clinically-driven target lesion revascularization (cd-TLR) defined as repeat PCI or CABG to the target lesion

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  8. Sekundärer Endpunkt

    Clinically-driven target vessel revascularization (cd-TVR)

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  9. Sekundärer Endpunkt

    Major adverse cardiac event (MACE) defined as composite of death, MI, or repeat cd-TLR

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  10. Sekundärer Endpunkt

    Target lesion failure (TLF) defined as composite of cardiac death, TVMI, or cd-TLR

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  11. Sekundärer Endpunkt

    Target vessel failure (TVF) defined as composite of cardiac death, TVMI, or cd-TVR

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  12. Sekundärer Endpunkt

    Target lesion thrombosis (TLT) (definite or probable) according to Academic Research Consortium (ARC) definition

    Zeitrahmen hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

Daten

Startdatum24. Februar 2025 (tatsächlich)
Primärer Abschluss1. Februar 2027 (geschätzt)
Abschluss1. Februar 2031 (geschätzt)
Erstveröffentlichung2. August 2024 (tatsächlich)
Zuletzt aktualisiert24. April 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtApril 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

51 Studienzentren rekrutieren

United States

EinrichtungStadtBundesland oder RegionStatus
Lehigh Valley Hospital - Cedar CrestAllentownPennsylvaniaRekrutiert
AnMed Health Medical CenterAndersonSouth CarolinaRekrutiert
University of Michigan Health System - University HospitalAnn ArborMichiganRekrutiert
Piedmont Atlanta HospitalAtlantaGeorgiaRekrutiert
Emory University Hospital MidtownAtlantaGeorgiaRekrutiert
The University of Alabama at BirminghamBirminghamAlabamaRekrutiert
Kaleida HealthBuffaloNew YorkRekrutiert
Virtua Our Lady of Lourdes HospitalCamdenNew JerseyRekrutiert
Medical University of South Carolina (MUSC)CharlestonSouth CarolinaRekrutiert
Advocate Illinois Masonic Medical CenterChicagoIllinoisRekrutiert
The Lindner Research CenterCincinnatiOhioRekrutiert
BayCare Health SystemClearwaterFloridaRekrutiert
University Hospitals Cleveland Medical CenterClevelandOhioRekrutiert
OhioHealth Riverside Methodist HospitalColumbusOhioRekrutiert
Baylor Heart & Vascular HospitalDallasTexasRekrutiert
Saint Elizabeth HealthcareEdgewoodKentuckyRekrutiert
M Health Fairview ClinicEdinaMinnesotaRekrutiert
Parkview HealthFort WayneIndianaRekrutiert
North Florida Regional Medical CenterGainesvilleFloridaRekrutiert
Corewell HealthGrand RapidsMichiganRekrutiert
The Moses H Cone Memorial HospitalGreensboroNorth CarolinaRekrutiert
UPMC Pinnacle Harrisburg CampusHarrisburgPennsylvaniaRekrutiert
HCA Houston Medical CenterHoustonTexasRekrutiert
Huntsville HospitalHuntsvilleAlabamaRekrutiert
University of Kansas Medical CenterKansas CityKansasRekrutiert
Saint Lukes Mid America Heart InstituteKansas CityMissouriRekrutiert
Gundersen LutheranLa CrosseWisconsinRekrutiert
John L McClellan Memorial Veterans HospitalLittle RockArkansasRekrutiert
Medical Center of the RockiesLovelandColoradoRekrutiert
University of Miami HospitalMiamiFloridaRekrutiert
Providence Saint Patrick HospitalMissoulaMontanaRekrutiert
Midwest Cardiovascular InstituteNapervilleIllinoisRekrutiert
Vanderbilt University Medical CenterNashvilleTennesseeRekrutiert
TriStar Centennial Medical CenterNashvilleTennesseeRekrutiert
Montefiore Medical CenterNew YorkNew YorkRekrutiert
Cumc/NyphNew YorkNew YorkRekrutiert
Kansas City Heart Rhythm Institute (Midwest Heart and Vascular Specialist)Overland ParkKansasRekrutiert
The Valley HospitalParamusNew JerseyRekrutiert
Hospital of the University of PennsylvaniaPhiladelphiaPennsylvaniaRekrutiert
The Heart Hospital Baylor PlanoPlanoTexasRekrutiert
Oregon Health & Science University HospitalPortlandOregonRekrutiert
Rhode Island Hospital and Health Services - LifespanProvidenceRhode IslandRekrutiert
Saint Francis Hospital (Roslyn NY)RoslynNew YorkRekrutiert
CentraCare Heart & Vascular Center MN - Saint Cloud HospitalSaint CloudMinnesotaRekrutiert
University of Washington (UW) Medical CenterSeattleWashingtonRekrutiert
Stanford Hospital & ClinicsStanfordCaliforniaRekrutiert
Carondelet Saint MarysTucsonArizonaRekrutiert
Medstar Washington Hospital CenterWashington D.C.District of ColumbiaRekrutiert
Ascension Via Christi Saint FrancisWichitaKansasRekrutiert
Novant Health New Hanover Regional Medical CenterWilmingtonNorth CarolinaRekrutiert

1 weiteres Studienzentrum ist im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

Seit wir diesen Eintrag erstmals eingelesen haben, wurden keine Änderungen erfasst.

Eine Änderung wird jedes Mal erfasst, wenn der Sponsor den Registereintrag aktualisiert. Status, Daten, Teilnahme und Studienzentren erscheinen hier, sobald sie sich ändern.

Register: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06535854